Biocon surges as USFDA advisory committee approves its proposed biosimilar Trastuzumab

14 Jul 2017 Evaluate

Biocon is currently trading at Rs. 394.00, up by 27.35 points or 7.46% from its previous closing of Rs. 366.65 on the BSE.

The scrip opened at Rs. 388.75 and has touched a high and low of Rs. 399.50 and Rs. 385.00 respectively. So far 1,90,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 399.50 on 14-Jul-2017 and a 52 week low of Rs. 229.44 on 19-Jul-2016.

Last one week high and low of the scrip stood at Rs. 399.50 and Rs. 305.00 respectively. The current market cap of the company is Rs. 23,787.00 crore.

The promoters holding in the company stood at 60.68%, while Institutions and Non-Institutions held 21.43% and 17.89% respectively.

The US Food and Drug Administration (USFDA) Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab. The committee voted 16-0 in support of eligible indications of the reference product, Herceptin, which include HER2-positive breast cancer in the metastatic and adjuvant settings.

Mylan and Biocon’s proposed biosimilar trastuzumab is also under review by regulatory authorities in Australia, Canada, Europe and several emerging markets.

Mylan and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products. The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace.


Biocon Share Price

362.00 -4.40 (-1.20%)
27-Jan-2026 13:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.00
Dr. Reddys Lab 1238.90
Cipla 1321.60
Zydus Lifesciences 889.25
Lupin 2135.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×